All Releases
 |
Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2009
Nov 6, 2009
|
19.9 KB |
| |
RICHMOND, Va., Nov 06, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Insmed Inc. (Nasdaq: INSM), a biopharmaceutical company, today reported results for the third quarter and nine-months ended September 30, 2009.
Revenues for the third quarter ended September 30, 2009 were $2.5 million, as compared to $4.1 million for the corresponding pe...
|
|
Insmed To Host Third Quarter 2009 Conference Call
Oct 22, 2009
|
9.9 KB |
| |
RICHMOND, Va., Oct 22, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Insmed Inc. (Nasdaq: INSM), a biopharmaceutical company, today announced that it will host a conference call on Friday, November 6th, at 8:30 AM ET, to discuss its financial results for the third quarter 2009. Insmed intends to issue its quarterly financial results press...
|
|
Insmed Receives NASDAQ Deficiency Notice Relating to Minimum Bid Price
Sep 16, 2009
|
8.8 KB |
| |
RICHMOND, Va., Sept 16, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that on September 15, 2009 it received a NASDAQ Staff Deficiency Letter from The NASDAQ Stock Market. The NASDAQ Letter states that for the last 30 consecutive business days, the closing...
|
|
Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009
Aug 13, 2009
|
18.6 KB |
| |
RICHMOND, Va., Aug 13, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Insmed Inc. (Nasdaq: INSM), a biopharmaceutical company, today reported results for the second quarter and six-months ended June 30, 2009.
Revenues for the second quarter ended June 30, 2009 were $3.0 million, up from $2.7 million for the corresponding period in 2008. T...
|
|
Insmed to Host Second Quarter 2009 Conference Call
Jul 31, 2009
|
9.8 KB |
| |
RICHMOND, Va., July 31, 2009 /PRNewswire via COMTEX News Network/ -- Insmed Inc. (Nasdaq: INSM), a biopharmaceutical company, today announced that it will host a conference call on Thursday, August 13(th), at 8:30 AM ET, to discuss its financial results for the second quarter 2009. Insmed intends to issue its quarterly financial results press rele...
|
|
Insmed Provides Update on Supply of IPLEX(TM)
Jul 27, 2009
|
10.2 KB |
| |
RICHMOND, Va., July 27, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Insmed Inc. (Nasdaq: INSM), a biopharmaceutical company, today announced that, effective immediately, the Company will cease the supply of IPLEX((TM)) to any new patients. In addition, the Company will not initiate further clinical trials with IPLEX((TM)) at this time. ...
|
|
Insmed Announces Addition to the Russell 3000(R) Index
Jun 30, 2009
|
8.5 KB |
| |
RICHMOND, Va., June 30, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Insmed Inc. (Nasdaq: INSM), a biopharmaceutical company, today announced that it has been added to the Russell 3000 Index following Russell Investments' reconstitution of its comprehensive set of U.S. and global equity indexes on June 26, 2009. Insmed was also added to ...
|
|
Insmed Announces Results of IPLEX(TM) Phase II Trial in Myotonic Muscular Dystrophy
Jun 25, 2009
|
11.9 KB |
| |
RICHMOND, Va., June 25, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Insmed Inc. (Nasdaq: INSM), a biopharmaceutical company, today announced results from its exploratory U.S. Phase II clinical trial evaluating IPLEX(TM) (mecasermin rinfabate) in patients with myotonic muscular dystrophy ("MMD"). The randomized, double-blind, placebo-con...
|
|
Insmed CEO Resigns Due to Health Concerns
Jun 15, 2009
|
10.4 KB |
| |
RICHMOND, Va., June 15, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Insmed Inc. (Nasdaq: INSM), a biopharmaceutical company, today announced that Geoffrey Allan, Ph.D. has resigned as Insmed's President, Chief Executive Officer and Chairman of the Board of Directors, effective immediately, due to a health condition. Dr. Allan has served...
|
|
Insmed Announces First Quarter 2009 Financial Results
May 13, 2009
|
18.0 KB |
| |
RICHMOND, Va., May 13, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Insmed Inc. (Nasdaq: INSM), a biopharmaceutical company, today reported results for the first quarter ended March 31, 2009.
Recent Company Highlights
-- Follow-on Biologics Program
-- Finalized sale of follow-on biologics (FOB) assets to Merck &
...
|
|
Insmed Regains NASDAQ Compliance
May 5, 2009
|
8.5 KB |
| |
RICHMOND, Va., May 5, 2009 /PRNewswire via COMTEX News Network/ -- RICHMOND, Va., May 5 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM), a biopharmaceutical company, today announced that it has received notification from The NASDAQ Stock Market that it has regained compliance with the minimum $1.00 per share bid price requirement, and further,...
|
|
Insmed to Host First Quarter 2009 Conference Call
Apr 23, 2009
|
10.1 KB |
| |
RICHMOND, Va., April 23, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Insmed Inc. (Nasdaq CM: INSM), a biopharmaceutical company, today announced that it will host a conference call on Wednesday, May 13th at 8:30 AM ET, to discuss its financial results for the first quarter 2009. Insmed intends to issue its quarterly financial results pr...
|
|
Insmed Completes Sale of Follow-On Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million
Mar 31, 2009
|
10.0 KB |
| |
RICHMOND, Va., March 31, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Insmed Inc. (Nasdaq: INSM), a biopharmaceutical company, announced today that it has successfully closed the sale of all of the Company's assets related to its follow-on biologics business to a subsidiary of Merck & Co., Inc. As a result of this closing, Insmed has now...
|
|
Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM)
Mar 30, 2009
|
|
| |
RICHMOND, Va., March 30, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- INSMED WILL CONTINUE TO MANAGE ALS EAP IN ITALY AND ALL IPLEX(TM) INITIATIVES IN THE U.S.
IDIS WILL HAVE RESPONSIBILITY FOR REST OF WORLD
Insmed Inc. (Nasdaq: INSM), a biopharmaceutical company, today announced the signing of an agreement with IDIS, a private, UK-base...
|
|
Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule
Mar 25, 2009
|
8.9 KB |
| |
RICHMOND, Va., March 25, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics (FOB) and biopharmaceuticals, today announced that on Monday, March 23, 2009, NASDAQ issued a notice further extending the suspension of the rules requiring a minimum $1 closing bid price and those rules req...
|
|
Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results
Mar 11, 2009
|
19.7 KB |
| |
RICHMOND, Va., March 11, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics (FOB) and biopharmaceuticals, today reported results for the quarter and full-year ended December 31, 2008.
Company HighlightsFollow-on Biologics ProgramInsmed entered into a definitive agreement with Merck...
|
|
Insmed Announces FDA Issues Statement Regarding Position on Allowing Patients With ALS Access to IPLEX(TM) Under an IND
Mar 10, 2009
|
9.3 KB |
| |
RICHMOND, Va., March 10, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics (FOB) and biopharmaceuticals, today announced that the U.S. Food and Drug Administration (FDA) has issued a statement on its website in regards to the agency's position on allowing patients with Amyotrophic ...
|
|
Insmed to Host Fourth Quarter and Full-Year 2008 Conference Call
Feb 26, 2009
|
9.6 KB |
| |
RICHMOND, Va., Feb 26, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Insmed Inc. (Nasdaq: INSM), a developer of biopharmaceuticals, today announced that it will host a conference call on Wednesday, March 11th at 8:30 AM ET, to discuss its financial results for the fourth quarter and year-end 2008. Insmed intends to issue its financial res...
|
|
Insmed Sells Follow-on Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million
Feb 12, 2009
|
12.5 KB |
| |
RICHMOND, Va., Feb 12, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Insmed Inc.
(Nasdaq: INSM), a developer of follow-on biologics and biopharmaceuticals
focused on niche markets with unmet medical needs, announced today that it has
entered into a definitive agreement with Merck & Co., Inc. whereby Merck,
through an affiliate, will pu...
|
|
Insmed and Premacure Announce European Orphan Designation for IPLEX(TM) in Retinopathy of Prematurity in Infants
Jan 21, 2009
|
11.8 KB |
| |
RICHMOND, Va., Jan 21, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics and biopharmaceuticals, and Premacure AB, a biopharmaceutical company dedicated to the development of, diagnosis and prevention of complications in neonates due to premature birth, today announced that the Eu...
|
|
|
